Boston Life Sciences Announces the Completion of it's Phase III THERAFECTIN Trial.BOSTON--(BUSINESS WIRE)--Aug. 18, 1997--Boston Life Sciences Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BLSI BLSI Boston Life Sciences, Inc. ) announced that it has completed its Phase III trial for Therafectin(TM), the company's oral drug for the treatment of Rheumatoid Arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. . The double-blind, placebo-controlled trial enrolled 218 patients at 25 sites in the U.S. Results are currently expected to be available within the next six to eight weeks, after clinical data has been collected from the sites and analyzed. "We are pleased to have completed this pivotal trial, which compared Therafectin to placebo in patients with active Rheumatoid Arthritis over a 20 week period," said Dr. Marc Lanser, chief scientific officer of BLSI. "The study was designed with very clear measurable end points, and we therefore expect unambiguous results," added Dr. Lanser. BLSI is developing novel treatments for cancer, autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause , and central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . In addition to THERAFECTIN, BLSI's products in clinical trials or in preclinical development include Troponin I troponin I n. A subunit of troponin found in muscle and cartilage that inhibits the formation of blood vessels and is under investigation as a potential cancer therapy. , a natural anti-angiogenesis factor for the treatment of solid tumors; Axogensis Factor 1. (AF-1), a novel central nervous system growth factor, Altropane(TM), a radioimaging agent for the diagnosis of Parkinson's Disease, and transcription, factors that may control the expression of molecules associated with autoimmune disease and allergies. CONTACT: Boston Life Sciences, Boston Marc E. Lanser, M.D. S. David Hillson 617/425-0200 or Martin E. Janis & Co. Inc. Bev Jedynak 312/943-1100 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion